IMMU-132, an SN-38 antibody-drug conjugate (ADC) targeting Τrop-2, as a novel platform for the therapy of diverse metastatic solid cancers: Clinical results.
Alexander Starodub
Research Funding - Immunomedics
Allyson J. Ocean
Research Funding - Immunomedics
Michael J. Guarino
Research Funding - Immunomedics
Vincent J. Picozzi
Research Funding - Immunomedics
Sajeve Samuel Thomas
No relevant relationships to disclose
Wells A. Messersmith
Research Funding - Immunomedics
Manish A. Shah
Research Funding - Immunomedics
Linda T. Vahdat
Research Funding - Immunomedics
Ellen Chuang
Research Funding - Immunomedics
Bruce S. Lin
Research Funding - Immunomedics
Serengulam V. Govindan
Stock Ownership - Immunomedics
Pius P Maliakal
Employment or Leadership Position - Immunomedics
William A. Wegener
Employment or Leadership Position - Immunomedics
Stock Ownership - Immunomedics
Steven A. Hamburger
Employment or Leadership Position - Immunomedics
Stock Ownership - Immunomedics (I)
Robert M. Sharkey
Employment or Leadership Position - Immunomedics
Stock Ownership - Immunomedics
David M. Goldenberg
Employment or Leadership Position - Immunomedics
Stock Ownership - Immunomedics (B)